Fractalkine/CX3CR1: Why a single chemokine-receptor duo bears a major and unique therapeutic potential

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 2, 2010, Pages 207-219

  D'Haese, Jan G ^a   Demir, Ihsan Ekin ^a   Friess, Helmut ^a   Ceyhan, Güralp O ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cancer; CX3CL1; CX3CR1; Fractalkine; Inflammation; Neuropathic pain; Therapeutic target

Indexed keywords

CATHEPSIN 5 INHIBITOR; CATHEPSIN S; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CX3CR1 ANTIBODY; CYSTEINE PROTEINASE INHIBITOR; FRACTALKINE; FRACTALKINE ANTAGONIST; GELATINASE A; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOLOGIC AGENT; INTERLEUKIN 2; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ALLERGIC ASTHMA; ALLODYNIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ATHEROSCLEROSIS; BONE MARROW METASTASIS; BRAIN METASTASIS; BRAIN REGION; BREAST CANCER; CELL ADHESION; CELL MIGRATION; CHRONIC PANCREATITIS; COLORECTAL CANCER; COLORECTAL DISEASE; DENDRITIC CELL; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFECT; DRUG PROTEIN BINDING; GLOMERULONEPHRITIS; INFLAMMATION; INNATE IMMUNITY; KIDNEY DISEASE; KIDNEY ISCHEMIA; LIVER CELL CARCINOMA; LUNG CARCINOMA; LUPUS ERYTHEMATOSUS NEPHRITIS; MICROGLIA; MONARTHRITIS; NEUROBLASTOMA; NEUROBLASTOMA CELL; NEUROPATHIC PAIN; NEUROPATHY; NOCICEPTION; NONHUMAN; PAIN ASSESSMENT; PANCREAS CANCER; PERIPHERAL NERVE INJURY; PERITONITIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN TARGETING; RECURRENCE RISK; REVIEW; RHINITIS; SCIATIC NERVE; SIGNAL TRANSDUCTION; SPINAL CORD INJURY; TUMOR CELL; TUMOR GROWTH; TUMOR LOCALIZATION; UPREGULATION;

ANIMALS; CHEMOKINE CX3CL1; HUMANS; INFLAMMATION; NEOPLASMS; PAIN; PANCREATIC DISEASES;

EID: 74949104597     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220903540265     Document Type: Review

References (96)

1. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12(2):121-127
2. Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997;385(6617):640-644
3. Fong AM, Robinson LA, Steeber DA, et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 1998;188(8):1413-1419
4. Garton KJ, Gough PJ, Blobel CP, et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 2001;276(41):37993-38001
5. Tsou CL, Haskell CA, Charo IF. Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of fractalkine. J Biol Chem 2001;276(48):44622-44626
6. Ludwig A, Hundhausen C, Lambert MH, et al. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. Comb Chem High Throughput Screen 2005;8(2):161-171
7. Clark AK, Yip PK, Grist J, et al. Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc Natl Acad Sci USA 2007;104(25):10655-10660
8. Lindia JA, McGowan E, Jochnowitz N, Abbadie C. Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain. J Pain 2005;6(7):434-438
9. Asensio VC, Campbell IL. Chemokines in the CNS: plurifunctional mediators in diverse states. Trends Neurosci 1999;22(11):504-512
10. Verge GM, Milligan ED, Maier SF, et al. Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Eur J Neurosci 2004;20(5):1150-1160
11. Hughes PM, Botham MS, Frentzel S, et al. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS. Glia 2002;37(4):314-327
12. Deiva K, Geeraerts T, Salim H, et al. Fractalkine reduces N-methyl-D-aspartate-induced calcium flux and apoptosis in human neurons through extracellular signal-regulated kinase activation. Eur J Neurosci 2004;20(12):3222-3232
13. Ceyhan GO, Deucker S, Demir IE, et al. Neural fractalkine expression is closely linked to pain and pancreatic neuritis in human chronic pancreatitis. Lab Invest 2009;89(3):347-361
14. Yasuda M, Ito T, Oono T, et al. Fractalkine and TGF-beta1 levels reflect the severity of chronic pancreatitis in humans. World J Gastroenterol 2008;14(42):6488-6495
15. Haskell CA, Hancock WW, Salant DJ, et al. Targeted deletion of CX3CR1 reveals a role for fractalkine in cardiac allograft rejection. J Clin Invest 2001;108(5):679-688
16. Combadiere C, Feumi C, Raoul W, et al. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J Clin Invest 2007;117(10):2920-2928
17. Chu L, Li X, Yu W, et al. Expression of fractalkine (CX3CL1) and its receptor in endotoxin-induced uveitis. Ophthalmic Res 2009;42(3):160-166
18. Zhuang ZY, Kawasaki Y, Tan PH, et al. Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkine. Brain Behav Immun 2007;21(5):642-651
19. Marchesi F, Piemonti L, Fedele G, et al. The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res 2008;68(21):9060-9069
20. Vitale S, Cambien B, Karimdjee BF, et al. Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancer. Gut 2007;56(3):365-372
21. Nishimura M, Umehara H, Nakayama T, et al. Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/ granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol 2002;168(12):6173-6180
22. Brand S, Hofbauer K, Dambacher J, et al. Increased expression of the chemokine fractalkine in Crohn's disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease Phenotype. Am J Gastroenterol 2006;101(1):99-106
23. Niess JH, Brand S, Gu X, et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 2005;307(5707):254-258
24. Bisset LR, Schmid-Grendelmeier P. Chemokines and their receptors in the pathogenesis of allergic asthma: progress and perspective. Curr Opin Pulm Med 2005;11(1):35-42
25. Rimaniol AC, Till SJ, Garcia G, et al. The CX3C chemokine fractalkine in allergic asthma and rhinitis. J Allergy Clin Immunol 2003;112(6):1139-1146
26. Blaschke S, Koziolek M, Schwarz A, et al. Proinflammatory role of fractalkine (CX3CL1) in rheumatoid arthritis. J Rheumatol 2003;30(9):1918-1927
27. Blaschke S, Muller GA. Fractalkine-a proinflammatory chemokine in rheumatoid arthritis. Zeitschrift fur Rheumatologie 2008;67(5):424-428
28. Reeves JD, McKnight A, Potempa S, et al. CD4-independent infection by HIV-2 (ROD/B): use of the 7-transmembrane receptors CXCR-4, CCR-3, and V28 for entry. Virology 1997;231(1):130-134
29. Faure S, Meyer L, Costagliola D, et al. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 2000;287(5461):2274-2277
30. Fong AM, Erickson HP, Zachariah JP, et al. Ultrastructure and function of the fractalkine mucin domain in CX3C chemokine domain presentation. J Biol Chem 2000;275(6):3781-3786
31. Harrison JK, Fong AM, Swain PA, et al. Mutational analysis of the fractalkine chemokine domain. Basic amino acid residues differentially contribute to CX3CR1 binding, signaling, and cell adhesion. J Biol Chem 2001;276(24):21632-21641
32. Yang XP, Mattagajasingh S, Su S, et al. Fractalkine upregulates intercellular adhesion molecule-1 in endothelial cells through CX3CR1 and the Jak Stat5 pathway. Circ Res 2007;101(10):1001-1008
33. Apostolakis S, Krambovitis E, Vlata Z, et al. CX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients: impact of pre-inflammatory stimuli and renin-angiotensin system modulators. Thromb Res 2007;121(3):387-395
34. Lucas AD, Bursill C, Guzik TJ, et al. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation 2003;108(20):2498-2504
35. Saederup N, Chan L, Lira SA, Charo IF. Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice: evidence for independent chemokine functions in atherogenesis. Circulation 2008;117(13):1642-1648
36. Galkina E, Ley K. Leukocyte influx in atherosclerosis. Curr Drug Targets 2007;8(12):1239-1248
37. Combadiere C, Potteaux S, Gao JL, et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 2003;107(7):1009-1016
38. Damas JK, Boullier A, Waehre T, et al. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler Thromb Vasc Biol 2005;25(12):2567-2572
39. Nassar BA, Nanji AA, Ransom TP, et al. Role of the fractalkine receptor CX3CR1 polymorphisms V249I and T280M as risk factors for early-onset coronary artery disease in patients with no classic risk factors. Scand J Clin Lab Invest 2008;68(4):286-291
40. Oh DJ, Dursun B, He Z, et al. Fractalkine receptor (CX3CR1) inhibition is protective against ischemic acute renal failure in mice. Am J Physiol 2008;294(1):F264-71
41. Furuichi K, Gao JL, Murphy PM. Chemokine receptor CX3CR1 regulates renal interstitial fibrosis after ischemia- reperfusion injury. Am J Pathol 2006;169(2):372-387
42. Durkan AM, Alexander RT, Liu GY, et al. Expression and targeting of CX3CL1 (fractalkine) in renal tubular epithelial cells. J Am Soc Nephrol 2007;18(1):74-83
43. Segerer S, Hughes E, Hudkins KL, et al. Expression of the fractalkine receptor (CX3CR1) in human kidney diseases. Kidney Int 2002;62(2):488-495
44. Inoue A, Hasegawa H, Kohno M, et al. Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum 2005;52(5):1522-1533
45. Nishiyori A, Minami M, Ohtani Y, et al. Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia? FEBS Lett 1998;429(2):167-172
46. Milligan ED, Zapata V, Chacur M, et al. Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats. Eur J Neurosci 2004;20(9):2294-2302
47. Cardona AE, Pioro EP, Sasse ME, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 2006;9(7):917-924
48. Hu P, Bembrick AL, Keay KA, McLachlan EM. Immune cell involvement in dorsal root ganglia and spinal cord after chronic constriction or transection of the rat sciatic nerve. Brain, Behavior, and Immunity 2007;21(5):599-616
49. Holmes FE, Arnott N, Vanderplank P, et al. Intra-neural administration of fractalkine attenuates neuropathic pain-related behaviour. J Neurochem 2008;106(2):640-649
50. Sun S, Cao H, Han M, et al. New evidence for the involvement of spinal fractalkine receptor in pain facilitation and spinal glial activation in rat model of monoarthritis. Pain 2007;129(1-2):64-75
51. Chen X, Geller EB, Rogers TJ, Adler MW. The chemokine CX3CL1/fractalkine interferes with the antinociceptive effect induced by opioid agonists in the periaqueductal grey of rats. Brain Res 2007;1153:52-57
52. Johnston IN, Milligan ED, Wieseler-Frank J, et al. A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci 2004;24(33):7353-7365
53. Davis CN, Zujovic V, Harrison JK. Viral macrophage inflammatory protein-II and fractalkine (CX3CL1) chimeras identify molecular determinants of affinity, efficacy, and selectivity at CX3CR1. Mol Pharmacol 2004;66(6):1431-1439
54. Milligan E, Zapata V, Schoeniger D, et al. An initial investigation of spinal mechanisms underlying pain enhancement induced by fractalkine, a neuronally released chemokine. Eur J Neurosci 2005;22(11):2775-2782
55. Chen S, Bacon KB, Li L, et al. In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II. J Exp Med 1998;188(1):193-198
56. Clark AK, Yip PK, Malcangio M. The liberation of fractalkine in the dorsal horn requires microglial cathepsin S. J Neurosci 2009;29(21):6945-6954
57. Sroga JM, Jones TB, Kigerl KA, et al. Rats and mice exhibit distinct inflammatory reactions after spinal cord injury. J Comp Neurol 2003;462(2):223-240
58. Dorgham K, Ghadiri A, Hermand P, et al. An engineered CX3CR1 antagonist endowed with anti-inflammatory activity. J Leukoc Biol 2009;86(4):903-911
59. Lavergne E, Combadiere B, Bonduelle O, et al. Fractalkine mediates natural killer-dependent antitumor responses in vivo. Cancer Res 2003;63(21):7468-7474
60. Xin H, Kikuchi T, Andarini S, et al. Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells. Eur J Immunol 2005;35(5):1371-1380
61. Tang L, Hu HD, Hu P, et al. Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma. Gene Ther 2007;14(16):1226-1234
62. Guo J, Chen T, Wang B, et al. Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1. Immunol Lett 2003;89(1):1-7
63. Guo J, Zhang M, Wang B, et al. Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells. Int J Cancer 2003;103(2):212-220
64. Nukiwa M, Andarini S, Zaini J, et al. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors. Eur J Immunol 2006;36(4):1019-1027
65. Robinson LA, Nataraj C, Thomas DW, et al. The chemokine CX3CL1 regulates NK cell activity in vivo. Cell Immunol 2003;225(2):122-130
66. Andre F, Cabioglu N, Assi H, et al. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol 2006;17(6):945-951
67. Jamieson WL, Shimizu S, D'Ambrosio JA, et al. CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res 2008;68(6):1715-1722
68. Nevo I, Sagi-Assif O, Meshel T, et al. The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells. Cancer Lett 2009;273(1):127-139
69. Ryu J, Lee CW, Hong KH, et al. Activation of fractalkine/CX3CR1 by vascular endothelial cells induces angiogenesis through VEGF-A/KDR and reverses hindlimb ischaemia. Cardiovasc Res 2008;78(2):333-340
70. Ohta M, Tanaka F, Yamaguchi H, et al. The high expression of fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol 2005;26(1):41-47
71. Matsubara T, Ono T, Yamanoi A, et al. Fractalkine-CX3CR1 axis regulates tumor cell cycle and deteriorates prognosis after radical resection for hepatocellular carcinoma. J Surg Oncol 2007;95(3):241-249
72. Zeng Y, Jiang J, Huebener N, et al. Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted IL-2. Cancer Lett 2005;228(1-2):187-193
73. Zeng Y, Huebener N, Fest S, et al. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. Cancer Res 2007;67(5):2331-2338
74. Shulby SA, Dolloff NG, Stearns ME, et al. CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res 2004;64(14):4693-4698
75. Castellana D, Zobairi F, Martinez MC, et al. Membrane microvesicles as actors in the establishment of a favorable prostatic tumoral niche: a role for activated fibroblasts and CX3CL1-CX3CR1 axis. Cancer Res 2009;69(3):785-793
76. Blum DL, Koyama T, M'Koma AE, et al. Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin Cancer Res 2008;14(23):7790-7797
77. Valdivia-Silva JE, Franco-Barraza J, Silva AL, et al. Effect of pro-inflammatory cytokine stimulation on human breast cancer: implications of chemokine receptor expression in cancer metastasis. Cancer Lett 2009;283(2):176-185
78. Ceyhan GO, Bergmann F, Kadihasanoglu M, et al. Pancreatic neuropathy and neuropathic pain-a comprehensive pathomorphological study of 546 cases. Gastroenterology 2009;136(1):177-186 e1
79. Ceyhan GO, Bergmann F, Kadihasanoglu M, et al. The neurotrophic factor artemin influences the extent of neural damage and growth in chronic pancreatitis. Gut 2007;56(4):534-544
80. Ceyhan GO, Demir IE, Rauch U, et al. Pancreatic neuropathy results in "neural remodeling" and altered pancreatic innervation in chronic pancreatitis and pancreatic cancer. Am J Gastroenterol 2009;104(10):2555-2565
81. Ceyhan GO, Michalski CW, Demir IE, et al. Pancreatic pain. Best Pract Res 2008;22(1):31-44
82. Demir IE, Ceyhan GO, Rauch U, et al. The microenvironment in chronic pancreatitis and pancreatic cancer induces neuronal plasticity. Neurogastroenterol Motil 2009: published online 12 November 2009, doi: 10.1111/j.1365-2982.2009.01428.x
83. Bockman DE, Buchler M, Beger HG. Interaction of pancreatic ductal carcinoma with nerves leads to nerve damage. Gastroenterology 1994;107(1):219-230
84. Brühl H, Cihak J, Schneider MA, et al. Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T cells. J Immunol 2004;172(2):890-898
85. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998;394(6696):894-897
86. Belperio JA, Keane MP, Burdick MD, et al. Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest 2001;108(4):547-556
87. Peters W, Scott HM, Chambers HF, et al. Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2001;98(14):7958-7963
88. Bird JE, Giancarli MR, Kurihara T, et al. Increased severity of glomerulonephritis in C-C chemokine receptor 2 knockout mice. Kidney Int 2000;57(1):129-136
89. Anders HJ, Frink M, Linde Y, et al. CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration. J Immunol 2003;170(11):5658-5666
90. Jung S, Aliberti J, Graemmel P, et al. Analysis of fractalkine receptor CX3CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 2000;20(11):4106-4114
91. Ishida Y, Hayashi T, Goto T, et al. Essential involvement of CX3CR1-mediated signals in the bactericidal host defense during septic peritonitis. J Immunol 2008;181(6):4208-4218
92. Liang M, Rosser M, Ng HP, et al. Species selectivity of a small molecule antagonist for the CCR1 chemokine receptor. Eur J Pharmacol 2000;389(1):41-49
93. Nomiyama H, Fukuda S, Iio M, et al. Organization of the chemokine gene cluster on human chromosome 17q11.2 containing the genes for CC chemokine MPIF-1, HCC-2, HCC-1, LEC, and RANTES. J Interferon Cytokine Res 1999;19(3):227-234
94. Cook DN, Chen SC, Sullivan LM, et al. Generation and analysis of mice lacking the chemokine fractalkine. Mol Cell Biol 2001;21(9):3159-3165
95. de Haas AH, van Weering HR, de Jong EK, et al. Neuronal chemokines: versatile messengers in central nervous system cell interaction. Mol Neurobiol 2007;36(2):137-151
96. Wasmuth HE, Zaldivar MM, Berres ML, et al. The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. J Hepatol 2008;48(2):208-215